Venetoclax + senescence-inducing chemotherapy
1 paper4 findings
- 1 lab in 1 country
- Funders: Abdul Hameed Shoman Foundation and 2 more
- Humans1
Associations
4Life-threatening outcomes
upin humans1
1 study
Life-threatening outcomes
upin humans1
Venetoclax + senescence-inducing chemotherapy is associated with life-threatening outcomes in humans (ROR 7.06, PRR 6.56, p < 0.001).
“combination therapy demonstrated higher reporting signals for life-threatening outcomes (ROR 7.06, PRR 6.56)”
Humanscompared with monotherapy
Journal of clinical medicine13 Mar 2026
Isolated low platelet count
downin humans1
1 study
Isolated low platelet count
downin humans1
Venetoclax + senescence-inducing chemotherapy is associated with isolated low platelet count in humans (ROR 0.31, PRR 0.32, p < 0.001).
“while isolated low platelet count was under-represented (ROR 0.31, PRR 0.32)”
Humanscompared with monotherapy
Journal of clinical medicine13 Mar 2026
Multi-lineage cytopenia
upin humans1
1 study
Multi-lineage cytopenia
upin humans1
Venetoclax + senescence-inducing chemotherapy is associated with multi-lineage cytopenia in humans (ROR 3.54, PRR 2.94, p < 0.001).
“multi-lineage cytopenias (ROR 3.54, PRR 2.94)”
Humanscompared with monotherapy
Journal of clinical medicine13 Mar 2026
Low wbc
upin humans1
1 study
Low wbc
upin humans1
Venetoclax + senescence-inducing chemotherapy is associated with low wbc in humans (ROR 2.87, PRR 2.59, p < 0.001).
“combination therapy showed disproportionate reporting signals (ROR/PRR; reflecting reporting disproportionality rather than incidence or causal risk) for low WBC (ROR 2.87, PRR 2.59)”
Humanscompared with monotherapy
Journal of clinical medicine13 Mar 2026